Esbriet Extends Survival Rates Among People with IPF by 30%

This topic contains 0 replies, has 1 voice, and was last updated by  Pulmonary Fibrosis News Moderator 9 months ago.

  • Author
    Posts
  • #15727

    Esbriet (pirfenidone) can improve survival rates of people with idiopathic pulmonary fibrosis by 30 percent, a real-world analysis shows. Learn more here.

    Are you being/have you been treated with Esbriet? How do you feel about this news?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account